

**Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab)  
Recombinant Antibody  
Catalog # APR10258****Specification****Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P08887</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

**Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) - Additional Information****Target/Specificity**

IL-6Ra / CD126

**Endotoxin**

&lt; 0.001EU/ µg, determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) - Protein Information****Name** IL6R ([HGNC:6019](#))**Function**

Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal (PubMed: [28265003](http://www.uniprot.org/citations/28265003)). Signal activation necessitate an association with IL6ST. Activation leads to the regulation of the immune response, acute-phase reactions and hematopoiesis (PubMed: [30995492](http://www.uniprot.org/citations/30995492), PubMed: [31235509](http://www.uniprot.org/citations/31235509)). The interaction with membrane-bound IL6R and IL6ST stimulates 'classic signaling', the restricted expression of the IL6R limits classic IL6 signaling to only a few tissues such as the liver and some cells of the immune system. Whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans- signaling'. Alternatively, 'cluster signaling' occurs when membrane- bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable).

### Cellular Location

[Isoform 1]: Cell membrane {ECO:0000250|UniProtKB:P22272}; Single-pass type I membrane protein [Soluble interleukin-6 receptor subunit alpha]: Secreted

### Tissue Location


[Isoform 2]: Expressed in peripheral blood mononuclear cells and weakly found in urine and serum. 1%-20% of the total sIL6R in plasma is generated by alternative splicing (PubMed:28060820).

## Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


## Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) - Images




Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 96.9%



The purity of Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) is more than 99.34%, determined by SEC-HPLC.



Immobilized human IL 6R His at 2 µg/mL can bind Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) EC50=0.0158 µg/mL



Human IL6R CHO cells were stained with Anti-IL-6Ra / CD126 Reference Antibody (vobarilizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC320=1.0090 nM